title: Renal allograft protection with early angiotensin-converting enzyme inhibitors administration.
abstract: Twenty renal transplant recipients (RTx) with a normal ultrasound pattern of renal artery who began angiotensin-converting enzyme inhibitor (ACEI) therapy within 14 months after surgery (ACEI(+)) were studied retrospectively to evaluate endogenous creatinine clearance/1.73 m(2) body surface area (CrCl), proteinuria (UP), UP/CrCl (FUP), mean arterial pressure (MBP), total cholesterol, LDL, HDL, and triglycerides. Before (T(0)) and every month for 2 years after initiation of ACEI. Twenty-four RTx who never received ACEI (ACEI(-)) were studied in the same fashion. No differences in the parameters were noted at T(0); all RTx had CrCl >60 mL/min, Up less than 0.5 g/d, and stable renal function for 3 months before the study. In the ACEI cohort CrCl was reduced after 2 years compared with T(0) (65.6 +/- 2.8 vs 76 +/- 3.2 mL/min, P <.004), UP and FUP were both increased (660 +/- 60 vs 130 +/- 20 mg/d, 8.9 +/- 1.3 vs 2.8 +/- 0.6 mg/mL x 10(3); P <.001 and.002, respectively). UP >0.5 g/d was present in three cases. After 2 years the ACEI(+) group showed a decrease in CrCl (68.2 +/- 3.1 vs 73 +/- 2.2 mL/min) and the increase in UP (181 +/- 21 vs 139 +/- 18 mg/d) and in FUP (3.1 +/- 0.7 vs 2.6 +/- 0.9 mg/mL x 10(3)), which were not significantly different from the values at T(0). No cases showed UP >0.5 g/d. Moreover UP (P <.04), FUP (P <.03) and the percent reduction of CrCl (11.2 +/- 2.5% vs 4.6 +/- 1.8%, P <.05) were greater among ACEI(-) than ACEI(+) patients at 2 years. ACEI(-) patients showed correlation between the percent reduction of CrCl and UP (r =.51, P <.04). The values of MBP and lipids did not reveal any significant difference between the two groups. In conclusion, this study suggests that ACEI have a renoprotective effect, when used early, and may also prevent chronic allograft nephropathy.
authors.affiliation: Division of Nephrology, "S.Maria della Misericordia" Hospital, Udine, Italy. mimmont@yahoo.it
authors.forename: D
authors.initials: D
authors.lastname: Montanaro
authors.forename: M
authors.initials: M
authors.lastname: Gropuzzo
authors.forename: P
authors.initials: P
authors.lastname: Tulissi
authors.forename: G
authors.initials: G
authors.lastname: Boscutti
authors.forename: R
authors.initials: R
authors.lastname: Mioni
authors.forename: A
authors.initials: A
authors.lastname: Risaliti
authors.forename: U
authors.initials: U
authors.lastname: Baccarani
authors.forename: G L
authors.initials: GL
authors.lastname: Adani
authors.forename: M
authors.initials: M
authors.lastname: Sainz
authors.forename: F
authors.initials: F
authors.lastname: Bresadola
authors.forename: G
authors.initials: G
authors.lastname: Mioni
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001794:Blood Pressure; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000378:metabolism; D006085:Graft Survival / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000502:physiology*; D011507:Proteinuria; D012189:Retrospective Studies; D014184:Transplantation, Homologous; D014280:Triglycerides / Q000097:blood
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D014280:Triglycerides; D002784:Cholesterol; D003404:Creatinine